Telix has entered into an agreement with @CuriumPharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx). 

The asset is an internationally approved diagnostic radiopharmaceutical used for infection imaging. The agreement also appoints Curium as the manufacturer of the product for Telix.

In bringing sales and marketing in-house, Telix plans to significantly augment commercial distribution and indication expansion. 

There is also significant potential to expand clinical utility of the diagnostic, including as a “companion imaging” tool for TLX66, Telix’s therapeutic bone marrow conditioning candidate for hematopoietic stem cell transplantation.

Read more on our website here:TLX66 has not received a marketing authorization in any jurisdiction.